Peptidomimetic protease inhibitors

Details for Australian Patent Application No. 2001288318 (hide)

Owner Vertex Pharmaceuticals Incorporated

Inventors Guo, Deqi; Victor, Frantz; Lamar, Jason Eric; Wang, Q. May; Snyder, Nancy June; Yip, Yvonne Yee Mai; Glass, John Irvin; Chen, Shu Hui; Parker III, Raymond Samuel; Sun, Xicheng David; Collado, Ivan; Babine, Robert Edward; Tebbe, Mark Joseph; Garcia-Paredes, Cristina; Jin, Ling

Agent Spruson & Ferguson

Pub. Number AU-B-2001288318

PCT Pub. Number WO02/18369

Priority 60/229,398 31.08.00 US; 60/277,641 21.03.01 US

Filing date 31 August 2001

Wipo publication date 13 March 2002

Acceptance publication date 6 September 2007

International Classifications

C07K 7/06 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

A61K 31/13 (2006.01) - Amines, e.g. amantadine

A61K 31/437 (2006.01)

A61K 31/7052 (2006.01)

A61K 31/713 (2006.01) - Double-stranded nucleic acids or oligonucleotides

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 38/21 (2006.01) Medicinal preparations containing peptides - Interferons

A61K 38/55 (2006.01) Medicinal preparations containing peptides - Protease inhibitors

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 1/16 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 31/14 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

C07K 5/02 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 5/023 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 5/027 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 5/03 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 7/02 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

C07K 14/18 (2006.01) Peptides having more than 20 amino acids

C12N 7/06 (2006.01) Viruses, e.g. bacteriophages

C12N 9/99 (2006.01) Enzymes, e.g. ligases (6.) - Enzyme inactivation by chemical treatment

Event Publications

6 April 2006 Assignment before Grant

  Eli Lilly and Company The application has been assigned to Vertex Pharmaceuticals Incorporated Assignments before Grant, Section 113 2002

6 September 2007 Application Accepted

  Published as AU-B-2001288318

27 September 2007 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 05 Sep 2007. Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000 2002

17 January 2008 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 05 Sep 2007 2002

24 January 2008 Standard Patent Sealed

13 September 2012 Extension of Term of Standard Patents

  Vertex Pharmaceuticals Incorporated The earliest first regulatory approval date provided by the patentee 06 Mar 2012 For the goods INCIVO telaprevir

27 September 2012 Extension of Term of Standard Patents

  Vertex Pharmaceuticals Incorporated The earliest first regulatory approval date provided by the patentee 06 Mar 2012 For the goods INCIVO telaprevir Address for service in Australia: Shelston IP 60 Margaret Street Sydney NSW 2000

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2001288319

2001288317